AG Boor:Our research focuses on improved diagnostic, understanding of progression and treatment of chronic kidney disease (CKD), the common end-point of virtually all renal diseases, and on cardiovascular consequences of CKD. From methodological perspective, our main focus and expertise is in using, developing and refining animal models of kidney diseases, invasive and non-invasive in-vivo imaging, full spectrum nephropathological analyses (including electron microscopy) and artificial intelligence (particularly deep learning). (www.LaBooratory.ukaachen.de)
AG Kramann: We are studying renal and cardiac fibrosis and atherosclerosis and aim to identify novel therapeutic targets via single cell genomic technologies. We use genetic fate tracing, transgenic animal models, in vitro and in vivo CRISPR/Cas9 gene editing and organoids to preclinically validate targets and develop new therapeutic strategies
AG Moeller: We are investigating glomerular diseases in the kidney to develop novel therapeutic concepts. We also study how the kidney filter might work and why glomerular disease leads to proteinuria. For this we employ a broad spectrum of available methods such as transgenic animal models, isolated perfused kidneys, telemetric blood pressure measurements, high-end microscopy or single-cell transcriptomes.
AG Ostendorf/Floege: In the context of diagnosis and therapy of glomerular and tubulointerstitial kidney diseases, we focus on the research of central, pathophysiologically relevant mediators and their receptors in preclinical studies. In the recent past, we identified pro-fibrotic, pro-angiogenic, blood pressure-regulating and anti-proliferative molecules and systems that play a central role in the progression of kidney diseases and whose manipulation in preclinical medicine has shown new therapeutic potential. Using a broad spectrum of experimental models of renal inflammation and kidney damage, (conditional) transgenic animals, up-to date molecular and histological techniques, we currently focusing on a) studying the role of platelet-derived growth factor C (PDGF-C) and its receptor and b) the renal serotonin/serotonin receptor system in acute and progressive renal diseases.
AG Raffetseder/Rauen: The goal of our research is to understand the molecular and cellular mechanisms of kidney disease and inflammation. We focus on the role of the highly conserved Y-box binding protein (YB-1) and its receptor Notch-3. In addition to organ-specific processes driven by YB-1 and Notch-3, we are also interested in the interaction between the kidney and other organs and the influence of the YB-1:Notch-3 axis on these organ cross-talks. Our methodological spectrum covers diverse kidney inflammation/damage models, transgenic animal models, and a broad spectrum of cutting-edge molecular techniques as well as histological and molecular tools.